Tuberculosis Management

Current Status
Not Enrolled
Get Started
This course is currently closed

Tuberculosis (TB) is a preventable and curable disease but remains one of the top infectious diseases worldwide, with more than 10 million new cases causing approximately 1.5 million deaths annually. In 2019 there were 2.5million people infected with TB and more than half a million TB related deaths registered in the African region according to World Health Organisation (WHO) report.

Pharmacists are essential members of the healthcare workforce and play a vital role in the care and management of TB patients. The purpose of this course is to equip pharmacists with knowledge and skills in the management of TB, anti-TB agents and regimens. Pharmacists will be empowered to use their expert knowledge in medicines to educate their patients, support other healthcare members and contribute effectively to overall patient care.

In this course, we will explore TB management and treatment.

Learning objectives

By the end of this course, you will be able to:

  • Discuss the treatment options for TB and resistant-TB
  • Describe the mechanism of action of different anti-TB medications
  • Recognise TB medication side effects, potential interactions and explain how to manage them
  • Discuss the management and considerations to changes in treatment regimens in specific patient groups e.g., pregnancy, children and those with HIV
  • Describe strategies to improve patient adherence to TB medication and provide adequate patient education, counselling, monitoring, and support.

Before we begin, have a go at completing the following quiz. The purpose of this quiz is solely to measure your baseline understanding prior to taking the course. There will be another quiz at the end of the course so you can compare scores and check your progress. Please note, this quiz can only be attempted once.

Tuberculosis programme acknowledgements

Author: Timothy Rennie
Reviewers: Manjiri Gharat, Manjula Halai, Mubita Mwangana, Chiko Savieli

Published: March 2022
Review date: March 2025